BCL2L1 and Familial prostate cancer: In order to demonstrate if DNAzyme-mediated down-regulation of the bcl-xL expression resulted in chemosensitization of tumour cells to anticancer drugs in vivo, a murine model with human PC3 prostate cancer xenograft was used to determine the sensitivity to the chemotherapeutic.